Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A

Blood

Volumn 116, Issue 16, 2010, Pages 3049-3057

  Shi, Qizhen ^a,b,c   Fahs, Scot A ^a   Kuether, Erin L ^a,b,c   Cooley, Brian C ^b   Weiler, Hartmut ^a,b   Montgomery, Robert R ^a,b,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Children's Hospital of Wisconsin ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TENDENCY; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HEMOPHILIA A; HEMOSTASIS; HORMONAL THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; WEIBEL PALADE BODY;

EID: 77958193310     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-272419     Document Type: Article

References (46)

1. High K. Gene-based approaches to the treatment of hemophilia. Ann N Y Acad Sci. 2002;961:63-64.
2. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem. 1999;274(28):19587-19592. (Pubitemid 129519399)
3. Doering CB, Josephson CD, Craddock HN, Lollar P. Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure. Blood. 2002;100(1):143-147. (Pubitemid 35177439)
4. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A. 2005;102(17):6080-6085. (Pubitemid 40594258)
5. Lamont PA, Ragni MV. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J Thromb Haemost. 2005;3(10):2259-2263.
6. Montgomery RR, Gill JC. Interactions between von Willebrand factor and factor VIII: where did they first meet. J Pediatr Hematol Oncol. 2000; 22(3):269-275.
7. Kumaran V, Benten D, Follenzi A, Joseph B, Sarkar R, Gupta S. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost. 2005;3(9):2022-2031.
8. Jacquemin M, Neyrinck A, Hermanns MI, et al. FVIII production by human lung microvascular endothelial cells. Blood. 2006;108(2):515-517.
9. Shovlin CL, Angus G, Manning RA, et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One. 2010;5(2):e9154.
10. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest. 2008;118(3):935-945.
11. Shahani T, Lavend'homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood. 2010;115(23):4902-4909.
12. Liu L, Mah C, Fletcher BS. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Mol Ther. 2006; 13(5):1006-1015.
13. Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule- delivered sleeping beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest. 2009;119(7):2086-2099.
14. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101(3):613-624.
15. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR. Expression of human factor VIII under control of the platelet-specific αIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab. 2003; 79(1):25-33. (Pubitemid 36579438)
16. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52(11):2757- 2764.
17. Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest. 1977;60(4):914-921.
18. Shi Q, Wilcox DA, Fahs SA, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest. 2006;116(7):1974-1982.
19. Shi Q, Fahs SA, Wilcox DA, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008;112(7):2713-2721.
20. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996; 87(7):1161-1169.
21. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7): 1171-1180. (Pubitemid 27010101)
22. Schlaeger TM, Bartunkova S, Lawitts JA, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997; 94(7):3058-3063.
23. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood. 1994;84(12):4214-4225.
24. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol. 1985;87:27-45. (Pubitemid 15029925)
25. Shi Q, Wilcox DA, Fahs SA, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007;5(2):352-361.
26. Lim YC, Garcia-Cardena G, Allport JR, et al. Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol. 2003;162(5):1591-1601.
27. Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC, Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008; 111(5):2647-2656.
28. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001; 21(9):1531-1537.
29. Cooley BC, Szema L, Chen CY, Schwab JP, Schmeling G. A murine model of deep vein thrombosis: characterization and validation in transgenic mice. Thromb Haemost. 2005;94(3):498-503. (Pubitemid 41300842)
30. Kukk E, Wartiovaara U, Gunji Y, et al. Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. Br J Haematol. 1997;98(1):195-203.
31. De PM, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007;28(12):519-524.
32. Venneri MA, De PM, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109(12):5276-5285.
33. Teng PI, Dichiara MR, Komuves LG, Abe K, Quertermous T, Topper JN. Inducible and selective transgene expression in murine vascular endothelium. Physiol Genomics. 2002;11(2):99-107.
34. Anghelina M, Moldovan L, Moldovan NI. Preferential activity of Tie2 promoter in arteriolar endothelium. J Cell Mol Med. 2005;9(1):113-121.
35. Li XM, Hu Z, Jorgenson ML, Slayton WB. High levels of acetylated low-density lipoprotein uptake and low tyrosine kinase with immunoglobulin and epidermal growth factor homology domains-2 (Tie2) promoter activity distinguish sinusoids from other vessel types in murine bone marrow. Circulation. 2009;120(19):1910-1918.
36. Olsen EH, McCain AS, Merricks EP, et al. Comparative response of plasma VWF in dogs to upregulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood. 2003;102(2):436-441.
37. Johnson MD, Kinter LB, Beeuwkes R III. Effects of AVP and DDAVP on plasma renin activity and electrolyte excretion in conscious dogs. Am J Physiol. 1979;236(1):F66-F70.
38. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest. 1976;57(6): 1618-1625.
39. Vischer UM, Wollheim CB. Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Haemost. 1997;77(6):1182-1188. (Pubitemid 27311992)
40. Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost. 2009; 7(11):1824-1831.
41. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer. 2006;46(5): 547-553.
42. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404.
43. Over J, Sixma JJ, Bouma BN, Bolhuis PA, Vlooswijk RA, Beeser-Visser NH. Survival of iodine-125-labeled factor VIII in patients with von Willebrand's disease. J Lab Clin Med. 1981; 97(3):332-344.
44. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529.
45. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2): 160-174.
46. Mullah-Ali AM, Chan AK, Lillicrap D, et al. Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A. Haemophilia. 2009;15(6):1258-1261.